La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Bio-Techne Bilan de santé
Santé financière contrôle des critères 6/6
Bio-Techne possède un total de capitaux propres de $2.1B et une dette totale de $319.0M, ce qui porte son ratio d'endettement à 15.4%. Son actif total et son passif total sont $2.7B et de $635.0M. L'EBIT de Bio-Techne est $207.4M ce qui fait que son ratio de couverture des intérêts 16.7. Elle dispose de liquidités et de placements à court terme de $152.9M.
Informations clés
15.4%
Ratio d'endettement
US$319.00m
Dette
Ratio de couverture des intérêts | 16.7x |
Argent liquide | US$152.86m |
Fonds propres | US$2.07b |
Total du passif | US$635.02m |
Total des actifs | US$2.70b |
Mises à jour récentes de la santé financière
These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Recent updates
When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jun 09Bio-Techne Corporation's (NASDAQ:TECH) Shares Climb 33% But Its Business Is Yet to Catch Up
May 21These 4 Measures Indicate That Bio-Techne (NASDAQ:TECH) Is Using Debt Reasonably Well
Apr 30Bio-Techne Corporation (NASDAQ:TECH) Shares Could Be 32% Above Their Intrinsic Value Estimate
Apr 15Bio-Techne: Secular Growth Opportunities Always Exhibit Financial Excellence
Apr 04We Think Bio-Techne (NASDAQ:TECH) Can Stay On Top Of Its Debt
Jan 17Bio-Techne Corporation (NASDAQ:TECH) Investors Are Less Pessimistic Than Expected
Dec 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Dec 05Is Now An Opportune Moment To Examine Bio-Techne Corporation (NASDAQ:TECH)?
Oct 10Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Sep 22A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Sep 01At US$80.80, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Jul 10Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Jun 22With EPS Growth And More, Bio-Techne (NASDAQ:TECH) Makes An Interesting Case
Jun 07Bio-Techne Corporation's (NASDAQ:TECH) Intrinsic Value Is Potentially 25% Below Its Share Price
May 23When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Apr 05Bio-Techne (NASDAQ:TECH) Has A Rock Solid Balance Sheet
Mar 21Here's Why We Think Bio-Techne (NASDAQ:TECH) Is Well Worth Watching
Mar 06When Should You Buy Bio-Techne Corporation (NASDAQ:TECH)?
Jan 03We Think Bio-Techne (NASDAQ:TECH) Can Manage Its Debt With Ease
Dec 15Should You Be Adding Bio-Techne (NASDAQ:TECH) To Your Watchlist Today?
Nov 30Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Nov 17Bio-Techne releases new AVV viral titer assays
Oct 11At US$291, Is Bio-Techne Corporation (NASDAQ:TECH) Worth Looking At Closely?
Sep 26Does Bio-Techne (NASDAQ:TECH) Have A Healthy Balance Sheet?
Sep 12Bio-Techne to seek shareholder approval for 4- for-1 stock split
Sep 01Is Now The Time To Put Bio-Techne (NASDAQ:TECH) On Your Watchlist?
Aug 29Bio-Techne releases Quantist Luminex data analysis software
Aug 18Estimating The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Aug 16Bio-Teche announces transition plan for CEO Kummeth
Aug 04Bio-Techne: Resiliency Comes At A Large Premium
Jul 29Analyse de la situation financière
Passif à court terme: Les actifs à court terme de TECH ( $617.4M ) dépassent ses passifs à court terme ( $159.4M ).
Passif à long terme: Les actifs à court terme de TECH ( $617.4M ) dépassent ses passifs à long terme ( $475.6M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: Le ratio dette nette/capitaux propres de TECH ( 8% ) est considéré comme satisfaisant.
Réduire la dette: Le ratio d'endettement de TECH a été réduit de 44.4% à 15.4% au cours des 5 dernières années.
Couverture de la dette: La dette de TECH est bien couverte par le flux de trésorerie opérationnel ( 93.7% ).
Couverture des intérêts: Les paiements d'intérêts de TECH sur sa dette sont bien couverts par l'EBIT ( 16.7 x couverture).